Company Encyclopedia
View More
name
SISRAM MED
01696.HK
Sisram Medical Ltd engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home use devices, injectables, and cosmeceuticals products in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio for various wellness businesses, including hair growth and removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue re-modelling injectables, personal care, and aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company also manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Copulla, Harmony, Accent, and LMNT brands.
133.60 B
01696.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking19/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.48%C
    • Profit Margin5.96%B
    • Gross Margin60.04%A
  • Growth ScoreD
    • Revenue YoY-3.30%D
    • Net Profit YoY-12.84%D
    • Total Assets YoY1.56%C
    • Net Assets YoY3.75%C
  • Cash ScoreC
    • Cash Flow Margin1678.92%B
    • OCF YoY-3.30%D
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreA
    • Gearing Ratio22.99%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SISRAM MED achieved double-digit growth in revenue for the third quarter

    SISRAM MED announced that the group's new orders in the third quarter maintained a strong growth momentum, mainly benefiting from the performance in the mainland, South Korea, and Thailand markets. The multifunctional flagship device Alma Harmony achieved steady growth this quarter. As a result, revenue recorded double-digit growth

    AASTOCKS·
    HK
    01696
    -0.47%
    AASTOCKS·
    HK
    01696
    -0.47%

    SISRAM MED's unaudited revenue for the third quarter achieved double-digit year-on-year growth and will orderly advance the commercialization process of Daxifei in mainland China

    SISRAM MED achieved double-digit year-on-year growth in unaudited revenue in the third quarter of 2025, mainly due to strong performance in the markets of China, South Korea, and Thailand. The group will continue to drive the penetration of the Soprano series in the Asia-Pacific region and accelerate the commercial deployment of Universkin by Alma in the U.S. market, while orderly advancing the commercialization process of Daxifei in mainland China

    Zhitong·
    HK
    01696
    -0.47%
    Zhitong·
    HK
    01696
    -0.47%

    Intel (Minutes): 18A is expected to contribute to profits by the end of 2026

    The following are the minutes of the Q3 2025 earnings call for $Intel(INTC.US) compiled by Dolphin Research. For an interpretation of the earnings report, please refer to "Intel: Stopping Losses and Recovering! Can the 'American SMIC' Poach TSMC?" 1. Core Financial Data of Intel's Earnings Report Q3 Financial Data: Revenue: $13.7 billion, exceeding the upper limit of the expected range, with a quarter-on-quarter growth of 6%. Gross Margin: (Non-GAAP) Gross margin was 40%, 4 percentage points higher than the performance guidance. This performance was attributed to revenue growth, improved product mix, and reduced inventory write-downs...

    HK
    00981
    -0.07%
    US
    TSM
    -0.85%
    US
    SFTBY
    +6.19%
    HK
    00981
    -0.07%
    US
    TSM
    -0.85%
    US
    SFTBY
    +6.19%

    Understanding the Market | SISRAM MED rose over 6% after signing a commercial distribution cooperation agreement with Fosun Pharma (Jiangsu)

    SISRAM MED rose over 6%, as of the time of writing, up 6.41%, priced at HKD 5.98, with a transaction volume of HKD 10.9752 million. In terms of news, SISRAM MED announced that SISRAM (Tianjin) and Fosun Pharma (Jiangsu) have signed a commercial distribution cooperation agreement. The group is responsible for providing commercial, marketing, medical education, and business planning services for the product injectable type A botulinum toxin, with the mainland trademark being Daxifei, in the region. The annual transaction cap for this agreement is USD 17 million, effective from yesterday until the end of this year and into the next year. The group indicated that this product is a re-licensed product by Fosun Pharma, used for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor supercilii muscles in adults. The group stated that the signing of the commercial distribution cooperation agreement will generate additional revenue

    Zhitong·
    HK
    01696
    -0.47%
    Zhitong·
    HK
    01696
    -0.47%

    SISRAM MED's subsidiary has reached a strategic cooperation with internationally renowned skincare expert Jamie Sherrill

    SISRAM MED's wholly-owned subsidiary Alma Lasers Ltd. has reached a strategic partnership with internationally renowned skincare expert Jamie Sherrill. This collaboration aims to enhance consumer engagement and solidify Alma's leadership position in the high-end aesthetic technology sector. Jamie Sherrill will serve as the strategic promotion representative for Alma's flagship equipment platform, leading global promotional activities to increase brand awareness and accelerate the market penetration of aesthetic solutions. This partnership is expected to enhance consumer awareness of Alma's high-end solutions and create new growth opportunities for clinics worldwide

    Zhitong·
    HK
    01696
    -0.47%
    Zhitong·
    HK
    01696
    -0.47%
    Posts
    View More

    $Amazon(AMZN.US) will likely announce between 12 AM and 2:30 AM tonight,

    the new Nova AI model + in-house Trainium 3 chip

    Given Alibaba and Google's stock rose after announcing new models, mindlessly go...

    $Nova Lifestyle(NVFY.US)💎 NVFY (Nova Lifestyle) — Order Book Snapshot 💎

    📈 Latest Price: $5.42

    📊 Buy Orders: 300.8K shares

    📊 Sell Orders: 30.7K shares

    🔥 Buy-side pressure dominates with a 10:1 ratio ...

    • 0
    © 2025 Longbridge｜Disclaimer